Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE EBITDA

EBITDA at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$125.93M+12.4%
Eli Lilly logo
Eli LillyLLY
——
Amgen logo
AmgenAMGN
——
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
Arrowhead Research logo
Arrowhead ResearchARWR
——
Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%—
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio2×-0.4×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

−$169.0Mebit+
$8.0MDepreciation Depletion & Amortization
=-$161M

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's EBITDA?
Ultragenyx Pharmaceutical (RARE) reported EBITDA of -$161M in Q1 2026.
How has Ultragenyx Pharmaceutical's EBITDA changed year-over-year?
Ultragenyx Pharmaceutical's EBITDA decreased by 20.1% year-over-year, from -$134M to -$161M.
What is the long-term trend for Ultragenyx Pharmaceutical's EBITDA?
Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's EBITDA has grown at a 7.9% compound annual growth rate (CAGR), from -$368.5M to -$500.06M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.